Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;24(10):3067-3072.
doi: 10.1245/s10434-017-5959-3. Epub 2017 Aug 1.

Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes

Jessemae L Welsh  1 , Tanya L Hoskin  2 , Courtney N Day  2 , Abigail S Thomas  2 , Jodie A Cogswell  2 , Fergus J Couch  3 , Judy C Boughey  4
Affiliations

Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes

Jessemae L Welsh et al. Ann Surg Oncol. 2017 Oct.

Abstract

Background: How diagnosis with a variant of uncertain significance (VUS) in a BRCA gene impacts clinical decision-making is not well known.

Methods: We queried for all patients attending Mayo Clinic Rochester from 2004 to 2016 who tested positive for BRCA1 or BRCA2 VUS and reviewed patient management choices. Groups were compared by using Wilcoxon rank-sum and Chi-square tests.

Results: We identified 97 patients (95 females, 2 males) with BRCA VUS. For patients without cancer history (n = 20), 80% had a mother or sister with breast cancer, and median Tyrer-Cuzick (IBIS) lifetime breast cancer risk score was 27% (range 16-62%). Management included bilateral prophylactic mastectomy (BPM) in 39%, where choice for BPM was significantly associated with IBIS score (median 32 vs. 24%, p = 0.02) and first-degree family history of breast cancer (100 vs. 64%, p = 0.03) but not Gail score or total number of family members with cancer. For patients with breast cancer who had known VUS status prior to surgery (n = 9), the rate of contralateral prophylactic mastectomy (CPM) was 22% compared with 25% without known VUS and 83% with known BRCA pathogenic mutation. In 21 of 97 (22%) patients, the BRCA VUS has been reclassified (95% benign, 5% deleterious).

Conclusions: BRCA VUS carriers with cancer elected surgical choices similar to average-risk breast cancer patients. However, VUS carriers without cancer had high rates of BPM, associated with first-degree family history and IBIS score. Over time, a significant proportion of BRCA VUS were reclassified, illustrating the importance of appropriate counseling regarding VUS.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Comparison of rates of surgical choices versus nonsurgical choices in patients without a cancer diagnosis who have a BRCA1 or BRCA2 variant of uncertain significance
FIG. 2
FIG. 2
Comparison of surgical choices of patients with and without cancer who were diagnosed with a BRCA1 or BRCA2 variant of uncertain significance
FIG. 3
FIG. 3
Surgical choices of patients with breast cancer diagnosed with a BRCA1 or BRCA2 variant of uncertain significance compared with breast cancer patients at Mayo Clinic Rochester with known BRCA1 or BRCA2 deleterious mutations and breast cancer patients with no known mutation or variant,
FIG. 4
FIG. 4
Illustration of reclassification of BRCA VUS
See this image and copyright information in PMC

References

    1. Nash R, Goodman M, Lin CC, Freedman RA, Dominici LS, Ward K, Jemal A. State variation in the receipt of a contralateral prophylactic mastectomy among women who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004–2012. JAMA Surg 2017. doi:10.1001/jamasurg. 2017.0115. - DOI - PMC - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed 30 March 2017.
    1. Murray ML, Cerrato F, Bennett RL, Jarvik GP. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genet Med. 2011;13(12):998–1005. - PubMed
    1. Chiba A, Hoskin TL, Hallberg EJ, Cogswell JA, Heins CN, Couch FJ, Boughey JC. Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1/BRCA2 mutation carriers with breast cancer. Ann Surg Oncol. 2016;23(10):3232–8. - PMC - PubMed
    1. Hoskin TL, Hieken TJ, Degnim AC, Jakub JW, Jacobson SR, Boughey JC. Use of immediate breast reconstruction and choice for contralateral prophylactic mastectomy. Surgery. 2016;159(4):1199–209. - PubMed

MeSH terms